Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Demattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002 Mar 22;295(5563):2264-7. PubMed Abstract, View on AlzSWAN

	Comments on Paper and Primary News

	Primary News: Early Diagnosis of Alzheimer's—Making Use of the Blood-Brain Barrier Comment by: Giulio Pasinetti
	Submitted 21 March 2002 \| Permalink	Posted 21 March 2002
	These data provide further support for the peripheral sink hypothesis, and suggest that the blood-brain-barrier may be a fine sieve for brain Ab that is substantially limited by plasma Aβ concentrations. If these findings can be... Read more These data provide further support for the peripheral sink hypothesis, and suggest that the blood-brain-barrier may be a fine sieve for brain Ab that is substantially limited by plasma Aβ concentrations. If these findings can be meaningfully replicated among other rodent models of Alzheimer's type, this may provide insight to the feasibility of this diagnostic measure in heterogeneous populations. However, in light of recent events surrounding the suspended trial of Elan's AN-1792 it is self-evident that we must use extreme caution in extrapolating experimental findings to the clinical setting. View all comments by Giulio Pasinetti

	Comment by: Benjamin Wolozin, ARF Advisor (Disclosure)
	Permalink
	It has previously been postulated that there is efflux of Aβ from the CNS to the periphery. This paper elegantly shows that this is the case, and in the process suggests a possible plasma test for assessing the CNS amyloid burden in Alzheimer patients. View all comments by Benjamin Wolozin

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:

Studied a large cohort (n = 49) of PDAPP mice homozygous (+/+) for the APPV717F transgene, all of which were 12 to 13 months of age. These mice begin to exhibit Ab and amyloid deposition in the brain at ~3 to 6 months of age. For the study each mouse received an intravenous (i.v.) injection of monoclonal antibody m266 (500 µg). Plasma samples from each animal were then obtained 5 min and 1, 3, 6, and 24 hours later. In each plasma sample, levels of Ab40 and Ab42 were assessed by enzyme-linked immunosorbent assay (ELISA).